Still, pharmaceutical marketers must remember that maintaining regulatory compliance is all-important.
The number of warning and untitled letters has dropped in recent years. Only four letters have been sent so far this year, compared to 28 in 2012.
The company "embraces" adverse-event reporting and knows not to expect monetary ROI from unbranded initiatives, says its US-based social media lead.
Medtronic, as part of the settlement, will pay $602,000 to a whistleblower to settle charges it caused physicians to submit false claims to federal health programs.
The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.
A young company is hoping its analytics platform can help doctors and pharma figure out who's going to stop taking their medication, and get them back on track.
The bad-ad watchdog issued an untitled letter to drugmaker Duchesnay in November.
The scandal over Diovan draws regulatory attention.
Some providers of CME are getting better at complying with accreditation criteria, data show, yet many are still struggling to meet a stricter set of requirements.
FDA's Office of Prescription Drug Promotion issued an Untitled Letter over what it says are misleading copy and overstated efficacy claims online.
The ad watchdog flagged the drug maker for what it said was yet another misleading Ampyra promotional piece.
For a country bent on healthcare cost control, findings represent an opportunity: authors say nearly 8% of the nation's total outlay could have been avoided.
GlaxoSmithKline's Dierdre Connelly peeled back the curtain on the company's sales force incentives revamp in a speech to the Pharmaceutical Regulatory and Compliance Congress, and pleaded for recognition that the industry had cleaned up the sketchy practices of the Blockbuster Era.
Pharma's med/legal/regulatory (MLR) teams, managers of risk and so often the scapegoats for creating roadblocks to digital innovation, were discussed in a much friendlier light by digital marketers at last week's ExL Digital Pharma East conference in Philadelphia.
GlaxoSmithKline is souping up its social media monitoring with a digital strategy it says will create processes that are standard enough to streamline communications, but flexible enough to meet local requirements.
GlaxoSmithKline's deal to resolve multiple US investigations into its sales and marketing practices—one of the largest settlements by a pharma company—aims to patch up several long-running legal disputes.
Agency CAHG became the first healthcare marketing shop to undergo training and certification in regulatory compliance through the Center for Communication Compliance, and its parent company, Omnicom, said all of its healthcare agencies will follow suit.
Asking consumers to gauge their risk for non-adherence, Merck is deploying a one-minute survey dubbed the Adherence Estimator that may be the way forward for keeping patients on-treatment.
Four out of five ads analyzed in a study of physician-directed pharmaceutical advertising would definitely not pass FDA muster, or might have trouble doing so, said researchers. Their findings may have implications for the FDA, DDMAC and the "Bad Ad" program.
Merck said it received a subpoena related to marketing and selling activities with respect to three drugs: Temodar, PegIntron and Intron A.
A national lab promised doctors they could enrich themselves by as much as $2 million a year through a scheme that involved billing payers multiple times for the same urinary drug test, a whistleblower suit alleges.
A company that markets a pill cap with a built-in cellular connection puts a social twist on getting patients to take their meds.
The FDA issued a warning to Canadian generic drug maker Apotex last month, marking the firm's second citation in less than a year.
Patients not taking or refilling medications on time costs the pharmaceutical industry billions each year. The housing bubble and recession have helped write a new chapter in the compliance story, as higher numbers of new prescriptions simply go unfilled because patients either cannot afford, or are unwilling, to pay for them.
Everyday Health is launching a condition-based "virtual doctor" feature for patients with chronic conditions that emphasizes compliance.
Pharmacies that counseled patients for a chronic COPD/respiratory drug saw an average increase in refill rates of more than 36% through the fifth fill, said McKesson.
Can pharma companies really predict the success of new product launches? Patrick Howie and Mike Luby report on how pharmas can hone in on physicians' actual prescribing behavior versus stated intentions